Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 18

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 18
---
 stage, or in the event we obtain
negative results, we will likely be unable to raise additional funding related to our HDAC studies or will have to change direction of
our research efforts regarding the HDAC inhibitor platform of candidate molecules.

Our
Manufacturing Strategy

We
have no manufacturing facilities that are owned or operated by us. We have performed laboratory scale synthesis and testing in our research
laboratories in Gaithersburg, Maryland. GMP synthesis of API, drug formulation and human dosage preparation will be performed under contracts
with third-party manufacturers.

13

Strategic
Agreements

We
have developed important strategic agreements with academic institutions for access to resources such as intellectual property, core
facilities and contracting relationships. In addition, we have established an agreement with Propagenix for intellectual property in-licensing.
Our current and ongoing relationships include:

    ●
    Georgetown
    University

    ○
    Sub-contractor
    for the SBIR supported African American prostate cancer patient health disparities project (completed). The conditional reprogramming
    of cells (CRC) technology was invented at Georgetown University and Georgetown University owns the intellectual property. Propagenix
    holds the license for the intellectual property for the CRC technology from Georgetown University. The intellectual property for
    cells derived from African American patients under the Georgetown University subcontract belong to Shuttle Pharmaceuticals, Inc.
    based on our sub-licensing agreement with Propagenix.

    ○
    Sub-contractor
    for the SBIR supported metabolomic predictive biomarker project (completed). The metabolomic biomarker intellectual property belongs
    to Georgetown University and Shuttle Pharma holds an exclusive option to license the intellectual property.

    ○
    Exclusive
    licensing agreement with Georgetown University pursuant to which Georgetown University agreed to license the intellectual property
    known as “Predictive Biomarkers for Adverse Effects of Radiation Therapy” (U.S. Patent Application No. 17/476,184, filed
    on September 15, 2021) (the “Patent Rights”), which was developed by Dr. Anatoly Dritschilo, the Company’s Chief
    Executive Officer, Dr. Scott Grindrod, the Company’s Principal Scientist, and Drs. Amrita Cheema and Yaoxiang Li, employees
    of Georgetown. The Patent Rights will be available for the Company’s use worldwide.

    ○
    Shuttle
    Pharma entered into a research agreement (the “Research Agreement”) with Georgetown University for testing